JP2006524254A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006524254A5 JP2006524254A5 JP2006513159A JP2006513159A JP2006524254A5 JP 2006524254 A5 JP2006524254 A5 JP 2006524254A5 JP 2006513159 A JP2006513159 A JP 2006513159A JP 2006513159 A JP2006513159 A JP 2006513159A JP 2006524254 A5 JP2006524254 A5 JP 2006524254A5
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- methyl
- benzimidazol
- piperidin
- pyridin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 125000000623 heterocyclic group Chemical group 0.000 claims 21
- 125000003118 aryl group Chemical group 0.000 claims 20
- 125000000217 alkyl group Chemical group 0.000 claims 16
- 150000001875 compounds Chemical class 0.000 claims 14
- 241000124008 Mammalia Species 0.000 claims 10
- 125000000753 cycloalkyl group Chemical group 0.000 claims 9
- 238000000034 method Methods 0.000 claims 9
- 125000001424 substituent group Chemical group 0.000 claims 8
- 125000000304 alkynyl group Chemical group 0.000 claims 7
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 6
- -1 4-{[4- (2-methyl-1H-benzimidazol-1-yl) piperidin-1-yl] methyl} phenyl Chemical group 0.000 claims 6
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 6
- 125000003342 alkenyl group Chemical group 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 125000005865 C2-C10alkynyl group Chemical group 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 125000005843 halogen group Chemical group 0.000 claims 5
- 229910052760 oxygen Inorganic materials 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 230000033115 angiogenesis Effects 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 230000003211 malignant effect Effects 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- BFQMNZSGJRJNHK-UHFFFAOYSA-N 1-ethyl-3-[1-methyl-6-[4-[[4-(2-oxo-3h-benzimidazol-1-yl)piperidin-1-yl]methyl]phenyl]-5-phenylpyrazolo[3,4-b]pyridin-3-yl]urea Chemical compound C1=C2C(NC(=O)NCC)=NN(C)C2=NC(C=2C=CC(CN3CCC(CC3)N3C(NC4=CC=CC=C43)=O)=CC=2)=C1C1=CC=CC=C1 BFQMNZSGJRJNHK-UHFFFAOYSA-N 0.000 claims 3
- WTOLMDZZQMSFOI-UHFFFAOYSA-N 3-[1-[[4-(3-amino-5-phenyl-2h-pyrazolo[3,4-b]pyridin-6-yl)phenyl]methyl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C1=C2C(N)=NNC2=NC(C=2C=CC(CN3CCC(CC3)N3C(NC4=CC=CC=C43)=O)=CC=2)=C1C1=CC=CC=C1 WTOLMDZZQMSFOI-UHFFFAOYSA-N 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- QEHLNDRCMQCNLS-UHFFFAOYSA-N methyl 3-amino-6-[4-[[4-(6-fluoro-1h-benzimidazol-2-yl)piperidin-1-yl]methyl]phenyl]-5-phenylfuro[2,3-b]pyridine-2-carboxylate Chemical compound C1=C2C(N)=C(C(=O)OC)OC2=NC(C=2C=CC(CN3CCC(CC3)C=3NC4=CC(F)=CC=C4N=3)=CC=2)=C1C1=CC=CC=C1 QEHLNDRCMQCNLS-UHFFFAOYSA-N 0.000 claims 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- CFZCFLONWSUZFP-UHFFFAOYSA-N 3-[1-[[4-(3-amino-1-methyl-5-phenylpyrazolo[3,4-b]pyridin-6-yl)phenyl]methyl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C=1C=C(CN2CCC(CC2)N2C(NC3=CC=CC=C32)=O)C=CC=1C=1N=C2N(C)N=C(N)C2=CC=1C1=CC=CC=C1 CFZCFLONWSUZFP-UHFFFAOYSA-N 0.000 claims 2
- YRJDTLJIZXAPEA-UHFFFAOYSA-N 3-[1-[[4-[3-amino-1-(2-hydroxyethyl)-5-phenylpyrazolo[3,4-b]pyridin-6-yl]phenyl]methyl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C1=C2C(N)=NN(CCO)C2=NC(C=2C=CC(CN3CCC(CC3)N3C(NC4=CC=CC=C43)=O)=CC=2)=C1C1=CC=CC=C1 YRJDTLJIZXAPEA-UHFFFAOYSA-N 0.000 claims 2
- MHSHJMBJLQWRBY-UHFFFAOYSA-N 3-[1-[[4-[3-amino-1-(2-morpholin-4-ylethyl)-5-phenylpyrazolo[3,4-b]pyridin-6-yl]phenyl]methyl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C12=NC(C=3C=CC(CN4CCC(CC4)N4C(NC5=CC=CC=C54)=O)=CC=3)=C(C=3C=CC=CC=3)C=C2C(N)=NN1CCN1CCOCC1 MHSHJMBJLQWRBY-UHFFFAOYSA-N 0.000 claims 2
- YNXIBVROBVAXTR-UHFFFAOYSA-N 3-[1-[[4-[3-amino-1-[2-(1h-imidazol-5-yl)ethyl]-5-phenylpyrazolo[3,4-b]pyridin-6-yl]phenyl]methyl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C12=NC(C=3C=CC(CN4CCC(CC4)N4C(NC5=CC=CC=C54)=O)=CC=3)=C(C=3C=CC=CC=3)C=C2C(N)=NN1CCC1=CNC=N1 YNXIBVROBVAXTR-UHFFFAOYSA-N 0.000 claims 2
- GEAIYSCJTKMVMR-UHFFFAOYSA-N 5-[4-[[4-(2-methylbenzimidazol-1-yl)piperidin-1-yl]methyl]phenyl]-6-phenyl-1h-imidazo[4,5-b]pyridine Chemical compound CC1=NC2=CC=CC=C2N1C(CC1)CCN1CC(C=C1)=CC=C1C1=NC=2N=CNC=2C=C1C1=CC=CC=C1 GEAIYSCJTKMVMR-UHFFFAOYSA-N 0.000 claims 2
- ULXDTDVFKRMXTL-UHFFFAOYSA-N 5-[4-[[4-(2-methylbenzimidazol-1-yl)piperidin-1-yl]methyl]phenyl]-6-phenyl-2h-triazolo[4,5-b]pyridine Chemical compound CC1=NC2=CC=CC=C2N1C(CC1)CCN1CC(C=C1)=CC=C1C1=NC=2N=NNC=2C=C1C1=CC=CC=C1 ULXDTDVFKRMXTL-UHFFFAOYSA-N 0.000 claims 2
- KHHTVAGKADOYOC-UHFFFAOYSA-N 9-[1-[[4-(3-amino-1-methyl-5-phenylpyrazolo[3,4-b]pyridin-6-yl)phenyl]methyl]piperidin-4-yl]purin-6-amine Chemical compound C=1C=C(CN2CCC(CC2)N2C3=NC=NC(N)=C3N=C2)C=CC=1C=1N=C2N(C)N=C(N)C2=CC=1C1=CC=CC=C1 KHHTVAGKADOYOC-UHFFFAOYSA-N 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 206010020751 Hypersensitivity Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 102000001708 Protein Isoforms Human genes 0.000 claims 2
- 108010029485 Protein Isoforms Proteins 0.000 claims 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- 208000026935 allergic disease Diseases 0.000 claims 2
- 230000007815 allergy Effects 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 201000008980 hyperinsulinism Diseases 0.000 claims 2
- 230000003463 hyperproliferative effect Effects 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 125000002950 monocyclic group Chemical group 0.000 claims 2
- VKJKNSCQTXORQP-UHFFFAOYSA-N n-[1-methyl-6-[4-[[4-(2-oxo-3h-benzimidazol-1-yl)piperidin-1-yl]methyl]phenyl]-5-phenylpyrazolo[3,4-b]pyridin-3-yl]acetamide Chemical compound C1=C2C(NC(=O)C)=NN(C)C2=NC(C=2C=CC(CN3CCC(CC3)N3C(NC4=CC=CC=C43)=O)=CC=2)=C1C1=CC=CC=C1 VKJKNSCQTXORQP-UHFFFAOYSA-N 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 claims 2
- 208000037803 restenosis Diseases 0.000 claims 2
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 claims 1
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 1
- 125000006664 (C1-C3) perfluoroalkyl group Chemical group 0.000 claims 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
- 229940122440 HIV protease inhibitor Drugs 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- 229940122054 Peroxisome proliferator-activated receptor delta agonist Drugs 0.000 claims 1
- 229940080774 Peroxisome proliferator-activated receptor gamma agonist Drugs 0.000 claims 1
- 229940123468 Transferase inhibitor Drugs 0.000 claims 1
- 125000005275 alkylenearyl group Chemical group 0.000 claims 1
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims 1
- 230000001028 anti-proliverative effect Effects 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 230000012820 cell cycle checkpoint Effects 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 230000001672 cytoproliferative effect Effects 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 239000002834 estrogen receptor modulator Substances 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 239000004030 hiv protease inhibitor Substances 0.000 claims 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 125000005010 perfluoroalkyl group Chemical group 0.000 claims 1
- 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 229940075993 receptor modulator Drugs 0.000 claims 1
- 102000027483 retinoid hormone receptors Human genes 0.000 claims 1
- 108091008679 retinoid hormone receptors Proteins 0.000 claims 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 claims 1
- 239000000849 selective androgen receptor modulator Substances 0.000 claims 1
- 230000007755 survival signaling Effects 0.000 claims 1
- 239000003558 transferase inhibitor Substances 0.000 claims 1
- 0 CC(*1)*(*)c2c1nc(-c1ccc(CN3CCC(*)CC3)cc1)c(-c1ccccc1)c2 Chemical compound CC(*1)*(*)c2c1nc(-c1ccc(CN3CCC(*)CC3)cc1)c(-c1ccccc1)c2 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US46512303P | 2003-04-24 | 2003-04-24 | |
| PCT/US2004/012187 WO2004096130A2 (en) | 2003-04-24 | 2004-04-20 | Inhibitors of akt activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006524254A JP2006524254A (ja) | 2006-10-26 |
| JP2006524254A5 true JP2006524254A5 (https=) | 2007-04-05 |
Family
ID=33418186
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006513159A Ceased JP2006524254A (ja) | 2003-04-24 | 2004-04-20 | Ａｋｔ活性の阻害剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7638530B2 (https=) |
| EP (1) | EP1620095A4 (https=) |
| JP (1) | JP2006524254A (https=) |
| CN (1) | CN1809351A (https=) |
| AU (1) | AU2004233827B2 (https=) |
| CA (1) | CA2522430A1 (https=) |
| WO (1) | WO2004096130A2 (https=) |
Families Citing this family (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101312736B1 (ko) | 2003-02-27 | 2013-09-27 | 팔라우 파르마 에스에이 | 피라졸로피리딘 유도체 |
| US20050113379A1 (en) * | 2003-09-05 | 2005-05-26 | Ping Ge | Heteroaryl fused pyridines, pyrazines and pyrimidines as CRF1 receptor ligands |
| WO2005061519A1 (en) | 2003-12-19 | 2005-07-07 | Takeda San Diego, Inc. | Kinase inhibitors |
| AU2005233584B2 (en) * | 2004-04-09 | 2010-12-09 | Merck Sharp & Dohme Corp. | Inhibitors of Akt activity |
| AU2005233569B2 (en) * | 2004-04-09 | 2010-08-19 | Merck Sharp & Dohme Corp. | Inhibitors of Akt activity |
| TW200618800A (en) * | 2004-08-03 | 2006-06-16 | Uriach Y Compania S A J | Heterocyclic compounds |
| EP1778669A2 (en) | 2004-08-18 | 2007-05-02 | Takeda San Diego, Inc. | Kinase inhibitors |
| US7544677B2 (en) | 2004-08-23 | 2009-06-09 | Merck & Co., Inc. | Inhibitors of Akt activity |
| ATE479687T1 (de) | 2004-10-15 | 2010-09-15 | Takeda Pharmaceutical | Kinaseinhibitoren |
| AR051596A1 (es) * | 2004-10-26 | 2007-01-24 | Irm Llc | Compuestos heterociclicos condensados nitrogenados como inhibidores de la actividad del receptor canabinoide 1; composiciones farmaceuticas que los contienen y su empleo en la preparacion de medicamentos para el tratamiento de trastornos alimentarios |
| PE20061119A1 (es) | 2005-01-19 | 2006-11-27 | Aventis Pharma Sa | PIRAZOLO PIRIDINAS SUSTITUIDAS COMO INHIBIDORES DE CINASAS FAK, KDR Y Tie |
| CN101115479A (zh) * | 2005-02-14 | 2008-01-30 | 默克公司 | Akt活性抑制剂 |
| WO2006123182A2 (en) | 2005-05-17 | 2006-11-23 | Merck Sharp & Dohme Limited | Cyclohexyl sulphones for treatment of cancer |
| US8008317B2 (en) * | 2005-06-10 | 2011-08-30 | Merck Sharp & Dohme Corp. | Inhibitors of akt activtiy |
| FR2889526B1 (fr) * | 2005-08-04 | 2012-02-17 | Aventis Pharma Sa | 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation |
| US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| US8017781B2 (en) | 2005-11-15 | 2011-09-13 | Vertex Pharmaceuticals Incorporated | Azaindazoles useful as inhibitors of kinases |
| WO2007087246A2 (en) | 2006-01-24 | 2007-08-02 | Merck & Co., Inc. | Jak2 tyrosine kinase inhibition |
| US8063050B2 (en) | 2006-07-06 | 2011-11-22 | Array Biopharma Inc. | Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
| ATE532789T1 (de) | 2006-07-06 | 2011-11-15 | Array Biopharma Inc | Dihydrothienopyrimidine als akt-proteinkinase- inhibitoren |
| EP2049500B1 (en) | 2006-07-06 | 2011-09-07 | Array Biopharma, Inc. | Cyclopenta [d] pyrimidines as akt protein kinase inhibitors |
| US8329701B2 (en) | 2006-07-06 | 2012-12-11 | Array Biopharma Inc. | Dihydrofuro pyrimidines as AKT protein kinase inhibitors |
| SG158147A1 (en) | 2006-10-09 | 2010-01-29 | Takeda Pharmaceutical | Kinase inhibitors |
| AR064010A1 (es) * | 2006-12-06 | 2009-03-04 | Merck & Co Inc | Inhibidores de la actividad de la akt |
| WO2008070823A2 (en) * | 2006-12-07 | 2008-06-12 | University Of South Florida | Substrate-mimetic akt inhibitor |
| EP1958947A1 (en) | 2007-02-15 | 2008-08-20 | Ranbaxy Laboratories Limited | Inhibitors of phosphodiesterase type 4 |
| US8642067B2 (en) | 2007-04-02 | 2014-02-04 | Allergen, Inc. | Methods and compositions for intraocular administration to treat ocular conditions |
| CN101918373B (zh) | 2007-07-05 | 2013-06-05 | 阵列生物制药公司 | 作为akt蛋白激酶抑制剂的嘧啶基环戊烷 |
| CN103396409B (zh) | 2007-07-05 | 2015-03-11 | 阵列生物制药公司 | 作为akt蛋白激酶抑制剂的嘧啶基环戊烷 |
| US8846683B2 (en) | 2007-07-05 | 2014-09-30 | Array Biopharma, Inc. | Pyrimidyl cyclopentanes as Akt protein kinase inhibitors |
| US9409886B2 (en) | 2007-07-05 | 2016-08-09 | Array Biopharma Inc. | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
| WO2009038784A1 (en) * | 2007-09-21 | 2009-03-26 | Amgen Inc. | Triazole fused heteroaryl compounds as p38 kinase inhibitors |
| US8853216B2 (en) | 2008-01-09 | 2014-10-07 | Array Biopharma, Inc. | Hydroxylated pyrimidyl cyclopentane as AKT protein kinase inhibitor |
| NZ586346A (en) | 2008-01-09 | 2012-02-24 | Array Biopharma Inc | Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors |
| US20100048524A1 (en) | 2008-03-14 | 2010-02-25 | Angela Brodie | Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity |
| CA2726317A1 (en) * | 2008-06-03 | 2009-12-10 | Merck Sharp & Dohme Corp. | Inhibitors of akt activity |
| EP2299825B1 (en) * | 2008-06-03 | 2013-07-31 | Merck Sharp & Dohme Corp. | Inhibitors of akt activity |
| ES2402087T3 (es) * | 2008-07-23 | 2013-04-26 | Vertex Pharmaceuticals Incorporated | Inhibidores de la pirazolopiridina quinasa |
| WO2010091306A1 (en) | 2009-02-05 | 2010-08-12 | Tokai Pharmaceuticals | Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens |
| AU2010213192A1 (en) * | 2009-02-13 | 2011-08-04 | Bayer Intellectual Property Gmbh | Fused pyrimidines |
| WO2010104705A1 (en) | 2009-03-12 | 2010-09-16 | Merck Sharp & Dohme Corp. | Inhibitors of akt activity |
| WO2010114780A1 (en) | 2009-04-01 | 2010-10-07 | Merck Sharp & Dohme Corp. | Inhibitors of akt activity |
| EP2464647B1 (en) | 2009-08-11 | 2016-09-21 | Bristol-Myers Squibb Company | Azaindazoles as btk kinase modulators and use thereof |
| US8859776B2 (en) | 2009-10-14 | 2014-10-14 | Merck Sharp & Dohme Corp. | Substituted piperidines that increase p53 activity and the uses thereof |
| GB0919380D0 (en) * | 2009-11-04 | 2009-12-23 | Almac Discovery Ltd | Pharmaceutical compouds |
| US8999957B2 (en) | 2010-06-24 | 2015-04-07 | Merck Sharp & Dohme Corp. | Heterocyclic compounds as ERK inhibitors |
| CA2805265A1 (en) | 2010-08-02 | 2012-02-09 | Merck Sharp & Dohme Corp. | Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina) |
| WO2012024170A2 (en) | 2010-08-17 | 2012-02-23 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| WO2012030685A2 (en) | 2010-09-01 | 2012-03-08 | Schering Corporation | Indazole derivatives useful as erk inhibitors |
| WO2012058210A1 (en) | 2010-10-29 | 2012-05-03 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA) |
| EP2654748B1 (en) | 2010-12-21 | 2016-07-27 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as erk inhibitors |
| KR102021157B1 (ko) | 2011-04-01 | 2019-09-11 | 제넨테크, 인크. | Ａｋｔ 억제제 화합물 및 아비라테론의 조합물, 및 사용 방법 |
| TR201815685T4 (tr) | 2011-04-01 | 2018-11-21 | Genentech Inc | Kanser tedavisi için akt ve mek inhibe edici bileşiklerin kombinasyonları. |
| EP2770987B1 (en) | 2011-10-27 | 2018-04-04 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
| US9408885B2 (en) | 2011-12-01 | 2016-08-09 | Vib Vzw | Combinations of therapeutic agents for treating melanoma |
| WO2013165816A2 (en) | 2012-05-02 | 2013-11-07 | Merck Sharp & Dohme Corp. | SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS |
| WO2014052563A2 (en) | 2012-09-28 | 2014-04-03 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
| ME02925B (me) | 2012-11-28 | 2018-04-20 | Merck Sharp & Dohme | Kompozicije i postupci za liječenje kancera |
| TW201429969A (zh) | 2012-12-20 | 2014-08-01 | Merck Sharp & Dohme | 作爲ｈｄｍ２抑制劑之經取代咪唑吡啶 |
| WO2014120748A1 (en) | 2013-01-30 | 2014-08-07 | Merck Sharp & Dohme Corp. | 2,6,7,8 substituted purines as hdm2 inhibitors |
| KR20150127720A (ko) | 2013-03-14 | 2015-11-17 | 유니버시티 오브 매릴랜드, 발티모어 | 안드로겐 수용체 하향 조절제 및 그의 용도 |
| CA2920317A1 (en) | 2013-08-12 | 2015-02-19 | Tokai Pharmaceuticals, Inc. | Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies |
| US20160194368A1 (en) | 2013-09-03 | 2016-07-07 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| WO2015103060A1 (en) * | 2014-01-06 | 2015-07-09 | Algomedix, Inc. | Trpa1 modulators |
| JP2019521189A (ja) * | 2016-07-06 | 2019-07-25 | アルゴメディックス，インク． | ドライアイ、眼痛および炎症の処置のためのｔｒｐａ１アンタゴニスト |
| JOP20190055A1 (ar) | 2016-09-26 | 2019-03-24 | Merck Sharp & Dohme | أجسام مضادة ضد cd27 |
| US10975084B2 (en) | 2016-10-12 | 2021-04-13 | Merck Sharp & Dohme Corp. | KDM5 inhibitors |
| CN118267470A (zh) | 2017-04-13 | 2024-07-02 | 赛罗帕私人有限公司 | 抗SIRPα抗体 |
| EP3706747B1 (en) | 2017-11-08 | 2025-09-03 | Merck Sharp & Dohme LLC | Prmt5 inhibitors |
| US10947234B2 (en) | 2017-11-08 | 2021-03-16 | Merck Sharp & Dohme Corp. | PRMT5 inhibitors |
| WO2019148412A1 (en) | 2018-02-01 | 2019-08-08 | Merck Sharp & Dohme Corp. | Anti-pd-1/lag3 bispecific antibodies |
| WO2020033282A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| EP3833669A4 (en) | 2018-08-07 | 2022-05-11 | Merck Sharp & Dohme Corp. | PRMT5 INHIBITORS |
| US11981701B2 (en) | 2018-08-07 | 2024-05-14 | Merck Sharp & Dohme Llc | PRMT5 inhibitors |
| WO2020033288A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| CN114981298B (zh) | 2019-12-12 | 2024-08-20 | 听治疗有限责任公司 | 用于预防和治疗听力损失的组合物和方法 |
| CN115003303B (zh) | 2019-12-17 | 2024-03-08 | 默沙东公司 | Prmt5抑制剂 |
| EP4076460B1 (en) | 2019-12-17 | 2026-01-21 | Merck Sharp & Dohme LLC | 1,4-dihydro-2h-spiro[isoquinoline-3,4'-piperidine derivatives as prmt5 inhibitors for the treatment of cancer |
| JP7589247B2 (ja) | 2019-12-17 | 2024-11-25 | メルク・シャープ・アンド・ドーム・エルエルシー | Ｐｒｍｔ５阻害剤 |
| US12595248B2 (en) | 2019-12-17 | 2026-04-07 | Merck Sharp & Dohme Llc | PRMT5 inhibitors |
| WO2026027944A1 (en) | 2024-07-30 | 2026-02-05 | Sairopa B.V. | Anti-sirp alpha antibody formulations and uses thereof |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW251284B (https=) | 1992-11-02 | 1995-07-11 | Pfizer | |
| GB9420521D0 (en) | 1994-10-12 | 1994-11-30 | Smithkline Beecham Plc | Novel compounds |
| US5972937A (en) | 1995-02-02 | 1999-10-26 | Smithkline Beecham P.L.C. | Heterocyclic compounds possessing 5HT2C receptor antagonist activity |
| RO115522B1 (ro) | 1995-02-02 | 2000-03-30 | Smithkline Beecham P.L.C. | Derivaţi de indolină, procedee pentru prepararea acestora, compoziţii farmaceutice care îi conţin şi metodă de tratament |
| GB9517559D0 (en) | 1995-08-26 | 1995-10-25 | Smithkline Beecham Plc | Novel compounds |
| US20020127214A1 (en) * | 1995-11-16 | 2002-09-12 | Hemmings Brian Arthur | RAC-protein kinase as therapeutic agent or in diagnostics |
| EP0868195A2 (en) | 1995-12-20 | 1998-10-07 | Medical Research Council | Control of protein synthesis, and screening method for agents |
| WO1997049704A1 (en) | 1996-06-27 | 1997-12-31 | Janssen Pharmaceutica N.V. | N-[4-(heteroarylmethyl)phenyl]-heteroarylamines |
| US6060491A (en) * | 1997-06-19 | 2000-05-09 | Dupont Pharmaceuticals | 6-membered aromatics as factor Xa inhibitors |
| ES2221213T3 (es) * | 1997-10-20 | 2004-12-16 | F. Hoffmann-La Roche Ag | Inhibidores de kinasa biciclicos. |
| GB0005642D0 (en) | 2000-03-10 | 2000-05-03 | Astrazeneca Uk Ltd | Chemical compounds |
| IL136458A0 (en) | 2000-05-30 | 2001-06-14 | Peptor Ltd | Protein kinase inhibitors |
| EP1317450B1 (en) * | 2000-09-15 | 2006-11-22 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US20040116433A1 (en) * | 2002-04-08 | 2004-06-17 | Owens Andrew Pate | Inhibitors of akt activity |
| US7034026B2 (en) | 2001-04-10 | 2006-04-25 | Merck & Co., Inc. | Inhibitors of Akt activity |
| US20040106540A1 (en) * | 2001-04-10 | 2004-06-03 | Barnett Stanley F | Method of treating cancer |
| WO2002083140A1 (en) * | 2001-04-10 | 2002-10-24 | Merck & Co., Inc. | Inhibitors of akt activity |
| WO2002083675A2 (en) * | 2001-04-10 | 2002-10-24 | Merck Sharp & Dohme Limited | Inhibitors of akt activity |
| EP1496981A2 (en) | 2002-04-08 | 2005-01-19 | Merck & Co., Inc. | Method of treating cancer |
| US7223738B2 (en) * | 2002-04-08 | 2007-05-29 | Merck & Co., Inc. | Inhibitors of Akt activity |
| EP1494675A4 (en) * | 2002-04-08 | 2006-07-19 | Merck & Co Inc | HEMMER OF ACT ACTIVITY |
| CA2481241C (en) * | 2002-04-08 | 2010-07-27 | Merck & Co., Inc. | Fused quinoxaline derivatives as inhibitors of akt activity |
| CA2480880C (en) * | 2002-04-08 | 2011-03-22 | Merck & Co., Inc. | Inhibitors of akt activity |
| CN100387598C (zh) * | 2002-09-16 | 2008-05-14 | 葛兰素集团有限公司 | 吡唑并[3,4-b]吡啶化合物及其作为磷酸二酯酶抑制剂的用途 |
| US20040102360A1 (en) * | 2002-10-30 | 2004-05-27 | Barnett Stanley F. | Combination therapy |
| JP2006507299A (ja) * | 2002-10-30 | 2006-03-02 | メルク エンド カムパニー インコーポレーテッド | Ａｋｔ活性の阻害薬 |
-
2004
- 2004-04-20 EP EP04760293A patent/EP1620095A4/en not_active Withdrawn
- 2004-04-20 CN CNA2004800171014A patent/CN1809351A/zh active Pending
- 2004-04-20 US US10/554,185 patent/US7638530B2/en not_active Expired - Fee Related
- 2004-04-20 CA CA002522430A patent/CA2522430A1/en not_active Abandoned
- 2004-04-20 WO PCT/US2004/012187 patent/WO2004096130A2/en not_active Ceased
- 2004-04-20 JP JP2006513159A patent/JP2006524254A/ja not_active Ceased
- 2004-04-20 AU AU2004233827A patent/AU2004233827B2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006524254A5 (https=) | ||
| TWI248932B (en) | Respiratory syncytial virus replication inhibitors | |
| AU2013361127B2 (en) | Compounds and methods for kinase modulation, and indications therefor | |
| AU2017395023B2 (en) | Compounds and methods for CDK8 modulation and indications therefor | |
| CA2787823C (en) | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same | |
| US10227357B2 (en) | Compounds and methods for kinase modulation, and indications therefor | |
| EP3268490B1 (en) | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations | |
| KR102066297B1 (ko) | 헤테로사이클릭 화합물 및 이의 유형 3 수용체 티로신 키나아제의 조절인자로서의 용도 | |
| JP2005525324A5 (https=) | ||
| JP2019512505A5 (https=) | ||
| CA2481241A1 (en) | Fused quinoxaline derivatives as inhibitors of akt activity | |
| JP2012525335A5 (https=) | ||
| IL187690A (en) | Derivatives 1, 2, 4 - Triazolo - 1, 6 - Naphthiridines as inhibitors of AKT activity for use in the preparation of drugs for the treatment of cancer | |
| RU2003106193A (ru) | Способ лечения аллергий с использованием замещенных пиразолов | |
| JP2006507299A5 (https=) | ||
| CA2670362A1 (en) | Compounds modulating c-fms and/or c-kit activity and uses therefor | |
| CA2501365A1 (en) | Inhibitors of akt activity | |
| JP2013507425A5 (https=) | ||
| SK287900B6 (sk) | Substituted azaindolexoacetic piperazine derivatives and pharmaceutical composition containing thereof | |
| JP7597709B2 (ja) | 置換インドールおよびインダゾール化合物 | |
| RU2005138546A (ru) | 2-имидазобензотиазолы, как лиганды аденозинового рецептора | |
| JP2005508942A5 (https=) | ||
| WO2019105734A1 (en) | Combinations of copanlisib | |
| RU2007105558A (ru) | Новые производные 2, 6-диаминопиридин-3-она | |
| US11185549B2 (en) | Combination of a PI3K-inhibitor with an androgen receptor antagonist |